| French, Craig |
| Recruiting | 2 | 450 | RoW | Denosumab 60 MG/ML, Prolia, Xgeva, Zoledronic Acid 5Mg/Bag 100Ml Inj, Zometa, Reclast, Aclasta, Sodium Chloride 0.9% or 5% Dextrose Intravenous, Saline, Placebo, Sodium Chloride 0.9% Injection | Australian and New Zealand Intensive Care Research Centre, Department of Health | Critical Illness, Osteoporosis | 02/27 | 02/27 | | |
| Wijeratne, Tissa |
POST-ETERNAL, NCT05105633: Extending the Time Window for Tenecteplase by Recanalization of Basilar Artery Occlusion in Posterior Circulation Stroke |
|
|
| Recruiting | 2/3 | 688 | RoW | Tenecteplase, Standard Care (which may include intravenous Alteplase) | University of Melbourne | Basilar Artery Occlusion | 08/26 | 12/26 | | |
| Kleinig, Timothy |
| Completed | 3 | 850 | Europe, Canada, US, RoW | Placebo, Nerinetide, NA-1 | NoNO Inc., University of Calgary | Stroke, Acute | 08/23 | 08/23 | | |
POST-ETERNAL, NCT05105633: Extending the Time Window for Tenecteplase by Recanalization of Basilar Artery Occlusion in Posterior Circulation Stroke |
|
|
| Recruiting | 2/3 | 688 | RoW | Tenecteplase, Standard Care (which may include intravenous Alteplase) | University of Melbourne | Basilar Artery Occlusion | 08/26 | 12/26 | | |
NCT05892510: Post-thrombectomy Intra-arterial Tenecteplase for Acute manaGement of Non-retrievable Thrombus and No-reflow in Emergent Stroke |
|
|
| Not yet recruiting | 2/3 | 462 | RoW | Intra-arterial tenecteplase injection at the completion of thrombectomy, Placebo | University of Melbourne | Ischemic Stroke, Acute, Cerebrovascular Disorders, Brain Disorder, Central Nervous System Diseases | 08/27 | 11/27 | | |
NCT03385928: STOP-MSU: Stopping Haemorrhage With Tranexamic Acid for Hyperacute Onset Presentation Including Mobile Stroke Units |
|
|
| Completed | 2 | 201 | Europe, RoW | Tranexamic Acid, Normal saline, 0.9%NaCl | Neuroscience Trials Australia, The Florey Institute of Neuroscience and Mental Health | Intracerebral Haemorrhage | 05/23 | 05/23 | | |
NCT05203224: Improving Early Reperfusion With Adjuvant Dornase Alfa in Large Vessel Ischemic Stroke (EXTEND-IA DNase) |
|
|
| Recruiting | 2 | 300 | RoW | Dornase Alfa, DNase, Pulmozyme | University of Melbourne | Ischemic Stroke | 09/25 | 12/25 | | |
EVACUATE, NCT04434807: Ultra-Early, Minimally inVAsive intraCerebral Haemorrhage evacUATion Versus Standard trEatment |
|
|
| Recruiting | N/A | 240 | RoW | Minimally invasive hematoma evacuation | University of Melbourne | Intra Cerebral Hemorrhage, Stroke | 12/25 | 12/26 | | |
| Johnston, Anna |
POLAR BEAR, NCT04332822 / 2018-003889-14: A Randomized, Multicenter, Phase III Trial Comparing Treatment With R-mini-CHOP With R-mini-CHP + Polatuzumab Vedotin in Patients With Diffuse Large Cell B Cell Lymphoma |
|
|
| Recruiting | 3 | 300 | Europe, RoW | R-pola-mini-CHP, R-mini-CHOP | Nordic Lymphoma Group, Roche Pharma AG | DLBCL, Diffuse Large B Cell Lymphoma | 12/25 | 12/28 | | |
BRUIN CLL-322, NCT04965493 / 2021-000043-49: A Trial of Pirtobrutinib (LOXO-305) Plus Venetoclax and Rituximab (PVR) Versus Venetoclax and Rituximab (VR) in Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) |
|
|
| Recruiting | 3 | 600 | Europe, Canada, Japan, US, RoW | Pirtobrutinib, LOXO-305, LY3527727, Venetoclax, Venclexta, Venclyxto, Rituximab, Rituxan, MabThera, Truxima, Riabni, Ruxience | Loxo Oncology, Inc., Eli Lilly and Company | Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma | 04/26 | 01/27 | | |
| Active, not recruiting | 3 | 650 | Europe, Canada, Japan, US, RoW | Pirtobrutinib, LOXO-305, LY3527727, Ibrutinib | Loxo Oncology, Inc., Eli Lilly and Company | Chronic Lymphocytic Leukemia, Leukemia, Lymphocytic, Leukemia, B-cell, Small Lymphocytic Lymphoma | 06/25 | 01/28 | | |
NCT04622943: An Interactive Web Platform to Teach Children Hunting, Shooting and Firearms Safety |
|
|
| Completed | N/A | 163 | US | firearms safety, nutrition | University of Alabama at Birmingham | Safety Issues, Injuries, Firearm Injury | 05/24 | 05/24 | | |
NCT03877744: Using Interactive Virtual Presence to Remotely Assist Parents With Child Restraint Installations |
|
|
| Completed | N/A | 1496 | US | interactive virtual presence, live technician | University of Alabama at Birmingham, Safe Kids Worldwide | Car Seat Installation | 02/24 | 02/24 | | |
| Active, not recruiting | N/A | 50 | US | self-rescue training | University of Alabama at Birmingham | Drowning | 11/24 | 12/24 | | |
| Barker, Kathryn |
NCT06100679: Responsible Engaged and Loving (REAL) Fathers Intervention Evaluation |
|
|
| Recruiting | N/A | 4728 | RoW | Responsible Engaged and Loving (REAL) Fathers Initiative, REAL Fathers | University of California, San Diego, Impact and Innovations Development Centre (IIDC), Uganda, NaNa Development Consultants Ltd, Uganda, LEGO Foundation | Violence, Gender-Based, Violence, Domestic, Violence, Sexual, Violence, Physical, Contraception Behavior, Child Development, Child Abuse, Communication, Partner, Conflict Resolution, Parent-Child Relations | 12/26 | 10/27 | | |
| Recruiting | N/A | 490 | RoW | Choice of home-based or centre-based pulmonary rehabilitation, Centre-based pulmonary rehabilitation | Monash University, Institute for Breathing and Sleep, Australia, University of Melbourne, La Trobe University, Thoracic Society of Australia and New Zealand, Lung Foundation Australia | Chronic Obstructive Pulmonary Disease | 12/24 | 12/25 | | |
| Celestino, Sherisse |
POST-ETERNAL, NCT05105633: Extending the Time Window for Tenecteplase by Recanalization of Basilar Artery Occlusion in Posterior Circulation Stroke |
|
|
| Recruiting | 2/3 | 688 | RoW | Tenecteplase, Standard Care (which may include intravenous Alteplase) | University of Melbourne | Basilar Artery Occlusion | 08/26 | 12/26 | | |
| Ciaccio, Pietro Di |
POLAR BEAR, NCT04332822 / 2018-003889-14: A Randomized, Multicenter, Phase III Trial Comparing Treatment With R-mini-CHOP With R-mini-CHP + Polatuzumab Vedotin in Patients With Diffuse Large Cell B Cell Lymphoma |
|
|
| Recruiting | 3 | 300 | Europe, RoW | R-pola-mini-CHP, R-mini-CHOP | Nordic Lymphoma Group, Roche Pharma AG | DLBCL, Diffuse Large B Cell Lymphoma | 12/25 | 12/28 | | |
